ATE213495T1 - Eine resorbierbare röntgenopake markierung enthaltendes chirurgisches implantat und verfahren zum verriegeln desselben in einem körper - Google Patents

Eine resorbierbare röntgenopake markierung enthaltendes chirurgisches implantat und verfahren zum verriegeln desselben in einem körper

Info

Publication number
ATE213495T1
ATE213495T1 AT97941068T AT97941068T ATE213495T1 AT E213495 T1 ATE213495 T1 AT E213495T1 AT 97941068 T AT97941068 T AT 97941068T AT 97941068 T AT97941068 T AT 97941068T AT E213495 T1 ATE213495 T1 AT E213495T1
Authority
AT
Austria
Prior art keywords
opacque
marker
locking
same
surgical implant
Prior art date
Application number
AT97941068T
Other languages
German (de)
English (en)
Inventor
Argyrios Georgios Arvanitis
Richard Eric Olson
Charles R Arnold Iii
William E Frietze
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Application granted granted Critical
Publication of ATE213495T1 publication Critical patent/ATE213495T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97941068T 1996-09-16 1997-09-15 Eine resorbierbare röntgenopake markierung enthaltendes chirurgisches implantat und verfahren zum verriegeln desselben in einem körper ATE213495T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2637396P 1996-09-16 1996-09-16
PCT/US1997/016252 WO1998011075A1 (fr) 1996-09-16 1997-09-15 Pyrazinones et triazinones ainsi que leurs derives

Publications (1)

Publication Number Publication Date
ATE213495T1 true ATE213495T1 (de) 2002-03-15

Family

ID=21831441

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97941068T ATE213495T1 (de) 1996-09-16 1997-09-15 Eine resorbierbare röntgenopake markierung enthaltendes chirurgisches implantat und verfahren zum verriegeln desselben in einem körper

Country Status (8)

Country Link
US (2) US6159980A (fr)
EP (1) EP0927171B1 (fr)
JP (1) JP2001502300A (fr)
AT (1) ATE213495T1 (fr)
AU (1) AU4270297A (fr)
CA (1) CA2265672C (fr)
DE (1) DE69710594T2 (fr)
WO (1) WO1998011075A1 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ301763B6 (cs) * 1998-08-20 2010-06-16 Toyama Chemical Co., Ltd. Protivirový prostredek a derivát dusíkatého heterocyklického karboxamidu
PT1129096E (pt) 1998-11-12 2003-09-30 Neurocrine Biosciences Inc Antagonistas de receptor de crf e metodos de tratamento relacionados com os mesmos
WO2000027846A2 (fr) 1998-11-12 2000-05-18 Neurocrine Biosciences, Inc. Antagonistes de recepteurs du crf et methodes associees
JP2003503476A (ja) * 1999-07-06 2003-01-28 バーテックス ファーマシューティカルズ インコーポレイテッド 環化アミド誘導体
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
EP1500653A1 (fr) * 2000-02-16 2005-01-26 Neurogen Corporation Arylpyrazines substituées
EE200200453A (et) 2000-02-16 2003-12-15 Neurogen Corporation Asendatud arüülpürasiinid
HUP0303038A2 (hu) 2000-09-21 2003-12-29 Bristol-Myers Squibb Co. Szubsztituált azolszármazékok mint kortikotropin releasing faktor inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
IL155505A0 (en) * 2000-10-27 2003-11-23 Dow Agrosciences Llc Substituted 4,5-dihydro-1,2,4-triazin-3 ones, 1,2,4-triazin-3-ones, and their use as fungicides and insecticides
BR0115243B1 (pt) * 2000-10-27 2013-09-17 4-5-diidro-1,2-4-triazin-6-onas,1,2,4-triazin-6-onas, composição fungicida ou inseticida, bem como método para controlar fungo ou inseto
ATE367814T1 (de) * 2001-03-15 2007-08-15 Janssen Pharmaceutica Nv Hiv hemmende pyrazinon-derivate
SK13752003A3 (en) * 2001-05-14 2004-11-03 Bristol Myers Squibb Pharma Co Substituted pyrazinones, pyridines and pyrimidines as ligands of factor releasing corticotropine
BR0211209A (pt) 2001-07-18 2004-07-13 Merck Patent Gmbh Derivados de 4-(benzilidenoamino)-3-(metilsulfanil)-4h-1,2,4-triazin- 5-ona tendo uma ação antagonìstica de tnf e inibição de pde iv para o tratamento de doenças cardìacas e alergias
US6638981B2 (en) 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
US6856007B2 (en) * 2001-08-28 2005-02-15 Tessera, Inc. High-frequency chip packages
US7335779B2 (en) * 2002-03-08 2008-02-26 Quonova, Llc Modulation of pathogenicity
US7338969B2 (en) * 2002-03-08 2008-03-04 Quonova, Llc Modulation of pathogenicity
JP2006509729A (ja) 2002-08-20 2006-03-23 ニューロジェン・コーポレーション Ｃｒｆ受容体モジュレータとしての５−置換−２−アリールピラジン類
MXPA05002418A (es) * 2002-09-12 2005-05-27 Pharmacia & Upjohn Co Llc Derivados de 1,4-pirazina sustituidos.
US20070197492A1 (en) * 2003-05-06 2007-08-23 Aldo Ammendola Modulation of Pathogenicity
JP2006525989A (ja) * 2003-05-09 2006-11-16 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Ｃｎｓ障害を治療するためのｃｒｆ１受容体アンタゴニストとしてのピラジノン
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US20080158821A1 (en) * 2004-11-30 2008-07-03 Telefonaktiebolaget Lm Ericsson (Publ) Printed Board Assembly with Improved Heat Dissipation
KR20080013990A (ko) * 2005-05-03 2008-02-13 다우 아그로사이언시즈 엘엘씨 치환된 4,5-디하이드로-1,2,4-트리아진-6-온,1,2,4-트리아진-6-온 및 살진균제로서의 이의 용도
RU2008129679A (ru) * 2005-12-21 2010-01-27 Янссен Фармацевтика Н.В. (Be) Новые замещенные пиразиноновые производные для применения при мсн-1-опосредованных заболеваниях
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
US20090011994A1 (en) * 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
NZ584145A (en) 2007-09-14 2012-03-30 Ortho Mcneil Janssen Pharm 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1,4'] bipyridinyl-2'-ones
EA019085B1 (ru) 2007-09-14 2014-01-30 Янссен Фармасьютикалз, Инк. 1',3-двузамещенные 4-(арил-х-фенил)-1н-пиридин-2-оны
EP2254420A4 (fr) 2008-02-20 2012-02-15 Targia Pharmaceuticals Compositions pharmaceutiques actives sur le snc et méthodes d'utilisation
EP2250156B1 (fr) * 2008-03-05 2015-05-06 Merck Patent GmbH Dérivés de pyrazinone comme stimulateurs de la sécrétion d'insuline, leurs procédés d'obtention et leur utilisation pour le traitement du diabète
US7932256B2 (en) * 2008-07-31 2011-04-26 Bristol-Myers Squibb Company (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
MX2011005242A (es) 2008-11-28 2011-09-06 Ortho Mcneil Janssen Pharm Derivados de indol y benzoxazina como moduladores de los receptores de glutamato metabotropicos.
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY161325A (en) 2009-05-12 2017-04-14 Janssen Pharmaceuticals Inc 1, 2, 4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
CA2760259C (fr) 2009-05-12 2018-05-01 Janssen Pharmaceuticals, Inc. Derives de la 1,2,4-triazolo [4,3-a] pyridine et leur utilisation en tant que modulateurs allosteriques positifs des recepteurs mglur2
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
CN103298809B (zh) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
IL296683B2 (en) 2014-01-21 2023-12-01 Neurocrine Biosciences Inc Preparations for the treatment of congenital adrenal hyperplasia
ME03518B (fr) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Combinaisons comprenant des modulateurs allostériques positifs de sous-type 2 de récepteurs glutamatergiques métabotropes et leur utilisation
WO2015110435A1 (fr) 2014-01-21 2015-07-30 Janssen Pharmaceutica Nv Combinaisons comprenant des modulateurs allostériques positifs ou des agonistes orthostériques de sous-type 2 de récepteur glutamatergique métabotrope, et leur utilisation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62198671A (ja) * 1986-02-25 1987-09-02 Toyo Jozo Co Ltd １−置換アルキル１，２−ジヒドロ−２−ピラジノン誘導体
DE4134467A1 (de) * 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
AU1191292A (en) * 1991-02-11 1992-09-07 Schering Agrochemicals Limited Imidazole pesticides
TW229142B (fr) * 1992-04-15 1994-09-01 Nissan Detrochem Corp
FR2692893B1 (fr) * 1992-06-24 1994-09-02 Sanofi Elf Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
TW370529B (en) * 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
EP0959074A3 (fr) * 1992-12-17 2000-06-07 Pfizer Inc. Pyrazoles substitués utilisés comme antagonistes du facteur de libération de corticotropine (CRF)
DK0674641T3 (da) * 1992-12-17 1999-09-27 Pfizer Pyrrolopyrimidiner som CRF-antagonister
WO1995010506A1 (fr) * 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyle-n-arylpyrimidinamines et leurs derives
CN1149870A (zh) * 1994-06-06 1997-05-14 辉瑞大药厂 具有促皮质激素释放因子拮抗剂活性的取代的吡唑
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
PL181895B1 (pl) * 1994-06-16 2001-10-31 Pfizer Nowe pirazolo-i pirolopirydyny _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ PL PL PL PL
TR199802133T2 (xx) * 1996-04-23 2000-09-21 Merck & Co., Inc. Pirazinon trombin inhibit�rleri.

Also Published As

Publication number Publication date
WO1998011075A1 (fr) 1998-03-19
DE69710594T2 (de) 2002-08-29
JP2001502300A (ja) 2001-02-20
DE69710594D1 (de) 2002-03-28
CA2265672A1 (fr) 1998-03-19
EP0927171B1 (fr) 2002-02-20
CA2265672C (fr) 2008-12-02
AU4270297A (en) 1998-04-02
EP0927171A1 (fr) 1999-07-07
US6218391B1 (en) 2001-04-17
US6159980A (en) 2000-12-12

Similar Documents

Publication Publication Date Title
ATE213495T1 (de) Eine resorbierbare röntgenopake markierung enthaltendes chirurgisches implantat und verfahren zum verriegeln desselben in einem körper
ATE255896T1 (de) Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
PL342078A1 (en) Inhibition of raf kinase using symmetrical and dissymmetrical substituted dimethylureas
PT97446A (pt) Processo para a preparacao de um derivado de tienobenzodiazepina, util como produto farmaceutico
PT93110A (pt) Processo aperfeicoado para a preparacao de derivados de isoquinolina
GR3029561T3 (en) Pyrrolopyrimidines as crf antagonists.
HK1060348A1 (en) Azolo-pyrimidines.
WO1997035539A3 (fr) Pyridines et pyrimidines a fusion arylamino
DE69939312D1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
EG18730A (en) Substituted tetralin, chromans and related compounds in the treatment of asthma, arthritis and related diseases
PT94993A (pt) Processo para a preparacao de 17 beta-(ciclopropilamino)-androst-5-en beta-ol 4 substituido e de compostos afins uteis como inibidores de liase c17-c20
BR9507980A (pt) Composto composição farmacêutica para uso no tratamento e/ou profilaxia de ansiedade mania depressão desordens associadas com uma hemorragia subaracnóide ou choke neural processo de tratamento e/ou profilaxia de ansiedade mania depressão desordens associadas com uma hemorragia subaracnóide ou choque neural composição farmacêutica uso de um composto
MY107449A (en) Bcrf1 proteins as inhibitors of interferon- gamma.
DE69128646D1 (de) Verfahren und zusammensetzung zur behandlung von hyperproliferativen hauterkrankungen unter verwendung von 6-aminopurin-cytokininen
ES2066096T3 (es) 4-bencil-5-fenil-2,4-dihidro-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
ZA902352B (en) Phytosanitary composition,its process of preparation and its use for treating cryptogamic diseases
DE69319341D1 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion
DE69833727D1 (de) Verfahren zur Behandlung der Gefässerkrankungen mit aktiviertem Protein C
DE3878529D1 (de) Vorrichtung zur behandlung von verstauchungen, insbesondere der sprunggelenke sowie zur vermeidung von dabei auftretenden bestimmten komplikationen.
WO1999016406A3 (fr) Methode therapeutique
DE69840863D1 (de) Verfahren zur Herstellung von 2,6-Diaminopurin-2'deoxyribosid und 2'-Deoxyguanosin
EP1380298A3 (fr) Tétrahydroptéridines et pyridylpipérazines pour le traitement de désordres neurologiques, anoréxie, inflammations
ATE62241T1 (de) Verfahren und vorrichtung zur herstellung von 5- methyl-7-diethylamino-s-triazolo(1,5-a)pyrimidin.
ATE161724T1 (de) Verfahren und zusammensetzung zur behandlung von hyperproliferativen hauterkrankungen unter verwendung von 6-aminopurin-cytokininen
ATE169486T1 (de) Formkörper, insbesondere für orthopädische zwecke, verfahren zu seiner herstellung, vorrichtung zur durchführung des verfahrens und verwendung des formkörpers

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties